Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meropenem
Drug ID BADD_D01393
Description Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
Indications and Usage For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
Marketing Status Prescription; Discontinued
ATC Code J01DH02
DrugBank ID DB00760
KEGG ID D02222
MeSH ID D000077731
PubChem ID 441130
TTD Drug ID D0O5FY
NDC Product Code 44567-146; 38217-0021; 70594-075; 72572-415; 70121-1453; 44567-401; 0781-3000; 70278-104; 0409-1390; 63323-508; 63323-507; 70594-076; 70121-1454; 70278-103; 0409-1391; 68083-146; 55150-208; 72572-416; 44647-032; 44567-145; 0781-3098; 52946-0839; 44567-400; 44647-033; 55150-207; 68001-324; 0069-0314; 38217-0020; 68083-147; 68001-447; 68001-323; 68001-446
Synonyms Meropenem | 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid | Merrem | Ronem | Penem | SM 7338 | SM-7338 | SM7338
Chemical Information
Molecular Formula C17H25N3O5S
CAS Registry Number 96036-03-2
SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Unresponsive to stimuli17.02.05.0310.000426%Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection11.01.10.002; 21.14.02.002--
Vaginal inflammation21.14.02.001--
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Wheezing22.03.01.0090.000213%
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.0130.000213%Not Available
Tubulointerstitial nephritis20.05.02.0020.000745%Not Available
Hypereosinophilic syndrome01.02.04.0050.000319%Not Available
Dermatosis23.03.03.0170.000213%Not Available
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.001065%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.000426%Not Available
Malignant neoplasm progression16.16.01.005--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Platelet count increased13.01.04.002--Not Available
Bone marrow toxicity12.03.01.006; 01.03.03.0040.000213%Not Available
Haemodynamic instability24.03.02.0060.000083%Not Available
Lymphatic disorder01.09.01.003--Not Available
Pruritus generalised23.03.12.0030.000213%Not Available
Candida sepsis11.03.03.0170.000083%Not Available
Transaminases increased13.03.01.0150.000213%Not Available
Haemorrhage24.07.01.002--Not Available
Toxic skin eruption10.01.01.008; 23.03.05.0030.000426%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000805%Not Available
Cardiac disorder02.01.01.0030.000222%Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages